General Motors Company (GM) and Ford Motor Company (F) Have Overcome Expectations for August

According to CNBC‘s Phil LeBeau, companies reported higher than predicted auto sales numbers for August. The sales of General Motors Company (NYSE:GM) dropped by 1.2%, down to 272,423 vehicles, opposed to the estimated fall of 2.5% and Ford Motor Company (NYSE:F)’s August sales picked up 0.4%, up to a total of 222,174 units, versus a decline of 1.3% that was expected.
Ford NYSE F
Ford Motor Company (NYSE:F) enjoyed a very productive month at the end of the summer, providing best August statistics in eight years. In a statement Ford said that: F-Series posted sixth consecutive month with over 60,000 units sold with a total number of 68,109 vehicles, Ford Explorer sales reached a pick of its August sales results since 2004 with 17,748 units sold and Ford Fusion has best month ever, in year-to-date sales best since its launch in 2005 posting 29,452 units sold.

“Both Fusion and Escape set records in August, each continuing on a strong pace toward 2014 being a best-ever sales year,” John Felice was quoted as saying.

Although General Motors Company (NYSE:GM) also outperformed analysts’ opinions, it still has displayed a decline in some numbers. Cadillac sales dropped by 18% to 16,650, Buick slipped 10%, reaching 22,143 cars, but Chevrolet Silverado increased by 13%,  totaling 49,201 vehicles, and GMC Sierra bounced 10% higher, up to 19,847 units sold.  Although the generalized figures for the amounts sold diminished, they did so compared to last year’s highest value, which is an overall optimistic comparison. Further in a press release on the official website, although General Motors Company (NYSE:GM) did not provide any exact predictions regarding the future of the company, they claimed having the best intentions to bring quality products.

General Motors Company (NYSE:GM) currently sells its stock at about $34.5 per share and seemingly tries to catch up with the July highs. Ford Motor Company (NYSE:F) can be bought at about $17.5 and the price fluctuations resemble the former company’s pattern, but show a little less deviation with respect to previous values. We can expect practically anything for the upcoming period in terms of sales and prices for these two companies, but numbers predict quite a prosperous year.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!